中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 10
Oct.  2018

Effect of salvianolic acid B on oxidative stress in a cell model of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2018.10.022
  • Published Date: 2018-10-20
  • Objective To establish a cell model of nonalcoholic fatty liver disease ( NAFLD) by inducing HepG2 cells with oleic acid ( OA) in vitro, and to investigate the effect of salvianolic acid B ( Sal B) on oxidative stress in NAFLD cells and its possible mechanisms via the intervention of NAFLD cells with Sal B. Methods HepG2 cells were divided into control group, model group ( treated with OA) , and intervention group ( treated with OA + Sal B) . The CCK8 method was used to plot the standard cell growth curve, and the optimal drug intervention concentration and intervention time were determined for OA. Oil red O staining was used to observe intracellular lipid accumulation.The levels of alanine aminotransferase ( ALT) , aspartate aminotransferase ( AST) , triglyceride ( TG) , and total cholesterol ( TC) were measured. A fluorescence microscope was used to measure the content of reactive oxygen species ( ROS) in cells. The TBA method was used to measure the content of malondialdehyde ( MDA) in cells. RT-qPCR and Western blot were used to measure the mRNA and protein expression of SOD2 and SIRT3. After SIRT3 was upregualted with SIRT3 overexpression plasmid, Sal B intervention was performed. Western blot was used to screen out the optimal ratio of transfection reagent to plasmid, and the change in relative expression of SIRT3 and SOD2 was measured. A one-way analysis of variance was used for comparison between multiple groups, and the least significant difference t-test was used for further comparison between two groups. Results The optimal concentration of OA for modeling was 1 mmol/L. The model group had higher levels of ALT and AST in cell culture supernatant than the control group, and the intervention group had lower levels of ALT and AST than the model group; there were significant differences between the three groups ( F = 1240. 075 and 471. 989, both P < 0. 05) . The model group had higher levels of TG and TC in cells than the control group, and the intervention group had lower levels of TG and TC than the model group; there were significant differences between the three groups ( F = 97. 530 and 39. 824, both P < 0. 01) . The model group had a higher MDA level than the control group, and the intervention group had a significantly lower MDA level than the model group; there was a significant difference between the three groups ( F = 336. 67, P < 0. 01) . There were significant differences in the mRNA expression of SIRT3 and SOD2 between the three groups ( F = 119. 35 and 32. 005, both P < 0. 01) ; the model group had significantly lower mRNA expression of SIRT3 and SOD2 than the control group ( P < 0. 05) , and the intervention group had significantly higher mRNA expression of SIRT3 and SOD2 than the model group ( P < 0. 05) . There were significant differences in the protein expression of SIRT3 and SOD2 between the three groups ( F = 67. 093 and 70. 314, both P < 0. 01) ; the model group had significantly lower protein expression of SIRT3 and SOD2 than the control group ( P < 0. 01) , and the intervention group had significantly higher protein expression of SIRT3 and SOD2 than the model group ( P < 0. 01) . The Western blot showed significant differences in the protein expression of SIRT3 and SOD2 between the empty plasmid+ Sal B group, plasmid group, empty plasmid group, and plasmid + Sal B group ( F = 287. 2 and 179. 8, both P < 0. 01) ; the empty plasmid + Sal B group and plasmid group had significantly higher protein expression of SIRT3 and SOD2 than the empty plasmid group ( P < 0. 05) , and the plasmid + Sal B group had significantly higher protein expression of SIRT3 and SOD2 than the plasmid group ( P < 0. 05) . Conclusion Sal B can reduce lipid accumulation and oxidative stress response in NAFLD cells and thus exert a protective effect on NAFLD cells.

     

  • [1]CHANG BX.An excerpt of EASL-EASD-EASO clinical practiceguidelines for the management of non-alcoholic fatty liver disease (2016) [J].J Clin Hepatol, 2016, 32 (8) :1450-1454. (in Chinese) 常彬霞.《2016年欧洲肝病学会、欧洲糖尿病学会和欧洲肥胖学会临床实践指南:非酒精性脂肪性肝病》摘译[J].临床肝胆病杂志, 2016, 32 (8) :1450-1454.
    [2]DAY CP, JAMES OF.Steatohepatitis:a tale of two“hits”?[J].Gastroenterology, 1998, 114 (4) :842-845.
    [3]TAO R, COLEMAN MC, PENNINGTON JD, et al.Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates Mn SOD activity in response to stress[J].Mol Cell, 2010, 40 (6) :893-904.
    [4]CHEN Y, ZHANG J, LIN Y, et al.Tumour suppressor SIRT3deacetylates and activates manganese superoxide dismutase to scavenge ROS[J].EMBO Rep, 2011, 12 (6) :534-541.
    [5]XUE L, WU Z, JI XP, et al.Effect and mechanism of salvianolicacid B on the myocardial ischemia-reperfusion injury in rats[J].Asian Pac J Trop Med, 2014, 7 (4) :280-284.
    [6]CHEN YS, LEE SM, LIN YJ, et al.Effects of Danshensu and Salvianolic Acid B from Salvia miltiorrhiza Bunge (Lamiaceae) on cell proliferation and collagen and melanin production[J].Molecules, 2014, 19 (2) :2029-2041.
    [7]WANG R, YU XY, GUO ZY, et al.Inhibitory effects of salvianolic acid B on CCl 4-induced hepatic fibrosis through regulating NF-kB/IkBαsignaling[J].J Ethnopharmacol, 2012, 144 (3) :592-598.
    [8]LI H, CHEN J, XU CH, et al.Antitumor effect of salvianolic acid A and on its reversal of multidrug resisitance in A549/MTX tumor[J].Chin J Clin Pharmacol Ther, 2017, 22 (11) :1244-1247. (in Chinese) 李晖, 陈俊, 徐彩虹, 等.丹酚酸A抗肿瘤作用及对逆转A549/MTX肿瘤多药耐药的影响[J].中国临床药理学与治疗学, 2017, 22 (11) :1244-1247.
    [9] ZENG W, SHAN W, GAO L, et al.Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease[J].Sci Rep, 2015, 5:16013.
    [10]XIA XH, LIU M, ZHANG ZM, et al.Antioxidant activity of water soluble constituents of Radix Salviae Miltiorrhizae in vitro[J].Chin Arch Tradit Chin Med, 2009, 27 (5) :1085-1087. (in Chinese) 夏鑫华, 刘梅, 张志敏, 等.丹参中水溶性成分体外抗氧化活性研究[J].中华中医药学刊, 2009, 27 (5) :1085-1087.
    [11]SHEN CY, JIANG JG, YANG L, et al.Anti-ageing active ingredients from herbs and nutraceuticals used in traditional Chinese medicine:pharmacological mechanisms and implications for drug discovery[J].Br J Pharmacol, 2017, 174 (11) :1395-1425.
    [12]WU HL, LI YH, LIN YH, et al.Salvianolic acid B protects human endothelial cells from oxidative stress damage:a possible protective role of glucose-regulated protein 78 induction[J].Cardiovasc Res, 2009, 81 (1) :148-158.
    [13]ZHAO M, ZHANG Y, ZHANG L, et al.Salvianolic acid B induces autophagic cell death in giloma through m TOR/Ulk1 signaling pathway[J].Chin J Immunol, 2018, 34 (4) :549-563. (in Chinese) 赵敏, 张瑜, 张岚, 等.丹酚酸B通过m TOR/Ulk1信号通路诱导胶质瘤细胞C6自噬性死亡[J].中国免疫学杂志, 2018, 34 (4) :549-563.
    [14]DONG S, LIU P, SUN MY.The pathogenesis of non-alcoholic fatty liver disease---Research progress of the“second strike”theory[J].J Clin Hepatol, 2012, 28 (7) :551-555. (in Chinese) 董姝, 刘平, 孙明瑜.非酒精性脂肪肝发病机制---“二次打击”学说研究进展[J].临床肝胆病杂志, 2012, 28 (7) :551-555.
    [15]OKAMOTO Y, TANAKA S, HAGA Y.Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model[J].Hepatol Res, 2002, 23 (2) :138-144.
    [16]LI J, LI X, LI Z, et al.Isofraxidin, a coumarin component improves high-fat diet induced hepatic lipid homeostasis disorder and macrophage inflammation in mice[J].Food Funct, 2017, 8 (8) :2886-2896.
    [17]NASSIR F, IBDAH JA.Role of mitochondria in nonalcoholicfatty liver disease[J].Int J Mol Sci, 2014, 15 (5) :8713-8742.
    [18]YESILOVA Z, YAMAN H, OKTENLI C, et al.Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease[J].Am J Gastroenterol, 2005, 100 (4) :850-855.
    [19]HO JH, HONG CY.Salvianolic acids:small compounds with multiple mechanisms for cardiovascular protection[J].J Biomed Sci, 2011, 18:30.
    [20]NASSIR F, ARNDT JJ, JOHNSON SA, et al.Regulation of mitochondrial trifunctional protein modulates nonalcoholic fatty liver disease in mice[J].J Lipid Res, 2018, 59 (6) :967-973.
    [21]ZENG X, YANG J, HU O, et al.Dihydromyricetin ameliorates nonalcoholic fatty liver disease by improving mitochondrial respiratory capacity and redox homeostasis through modulation of SIRT3 Signaling[J].Antioxid Redox Signal, 2018.[Epub ahead of print]
    [22]FINLEY LW, HAIGIS MC.Metabolic regulation by SIRT3:implications for tumorigenesis[J].Trends Mol Med, 2012, 18 (9) :516-523.
    [23]ZENG W, SHAN W, GAO L, et al.Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease[J].Sci Rep, 2015, 5:16013.
    [24]LV H, WANG L, SHEN J, et al.Salvianolic acid B attenuates apoptosis and inflammation via SIRT1 activation in experimental stroke rats[J].Brain Res Bull.2015, 115:30-36.
    [25]XU X, HU Y, ZHAI X, et al.Salvianolic acid A preconditioning confers protection against concanavalin A-induced liver injury through SIRT1-mediated repression of p66shc in mice[J].Toxicol Appl Pharmacol, 2013, 273 (1) :68-76.
    [26]WANG YC, KONG WZ, JIN QM, et al.Effect of salvi-anolic acid B on hepatocyte apoptosis in rats with nonalcoholic steatohepatitis[J].J Clin Hepatol, 2014, 30 (12) :1325-1329. (in Chinese) 王迎春, 孔维宗, 金青梅, 等.丹酚酸B对非酒精性脂肪性肝炎大鼠肝细胞凋亡的影响[J].临床肝胆病杂志, 2014, 30 (12) :1325-1329.
    [27]WANG Y, CHEN J, KONG W, et al.Regulation of SIRT3/FOXO1 signaling pathway in rats with non-alcoholic steatohepatitis by salvianolic acid B[J].Arch Med Res, 2017, 48 (6) :506-512.
  • Relative Articles

    [1]Yu ZHANG, Yongfeng YANG. Thinking of the pathological diagnosis of unexplained liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(3): 498-503. doi: 10.3969/j.issn.1001-5256.2023.03.003
    [2]Xixuan WANG, Liangzi DING, Yang CHENG, Hao HAN, Jian YANG, Jiangqiang XIAO, Yi WANG, Ming ZHANG, Feng ZHANG, Yuzheng ZHUGE. Value of liver stiffness measured by acoustic radiation force impulse in diagnosis of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2022, 38(11): 2488-2492. doi: 10.3969/j.issn.1001-5256.2022.11.010
    [3]Jialing ZHOU, Bingqiong WANG, Yameng SUN, Tongtong MENG, Shanshan WU, Hong MA, Xiaojuan OU, Hong YOU, Jidong JIA, Xiaoning WU. Application value of liver stiffness measurement-to-platelet ratio index score in diagnosis of hepatitis B liver fibrosis and liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1529-1533. doi: 10.3969/j.issn.1001-5256.2022.07.014
    [4]Zhongjie YU, Wenxia ZHAO, Leixin FENG, Hanxiao WANG, Jianpeng LIU. Value of five noninvasive diagnostic methods for liver cirrhosis in diagnosis of traditional Chinese medicine syndrome types in patients with compensated hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(1): 104-109. doi: 10.3969/j.issn.1001-5256.2022.01.016
    [5]Yajie XU, Wenzheng YOU, Wanlei REN, Quanhe LONG, Xiangjun JIANG, Doudou HU. Application of pathological indicators based on liver biopsy in the diagnosis of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2021, 37(12): 2935-2938. doi: 10.3969/j.issn.1001-5256.2021.12.042
    [6]Yu WANG, Min WANG, Guanhua ZHANG, Fuliang HE, Xiaojuan OU, Jidong JIA. Clinical diagnosis, staging, and therapeutic principles of liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 17-21. doi: 10.3969/j.issn.1001-5256.2021.01.004
    [7]NIU XingJie, LIU ZhiHui, CUI FengMei, LIU YaoMin, WANG YanFei, ZHANG GuoMin, LIU JinXia. Value of peripheral blood long non-coding RNA-LET in the diagnosis of chronic hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(12): 2709-2713. doi: 10.3969/j.issn.1001-5256.2020.12.014
    [8]Zhou ShengYun, Duan ZhiHui. Noninvasive diagnosis of esophageal varices in liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(8): 1842-1846. doi: 10.3969/j.issn.1001-5256.2020.08.036
    [9]Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. Journal of Clinical Hepatology, 2019, 35(10): 2163-2172. doi: 10.3969/j.issn.1001-5256.2019.10.007
    [10]Li JiaNa, Zheng RuiQi, Li Na, Hu YuLin. The biological characteristics of GP73 and its value in the diagnosis of liver fibrosis and cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1361-1364. doi: 10.3969/j.issn.1001-5256.2019.06.040
    [11]Zhang YaNan, Jiang Chang, Xu Ying, Gao YanHang. Early diagnosis of spontaneous bacterial peritonitis in liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1851-1853. doi: 10.3969/j.issn.1001-5256.2019.08.045
    [12]Liu HaiFeng, Xu YongSheng, Zhang Yue, Zhao XiaoJu, Liu Zhao, Li JinKui, Yan RuiFeng, Xu Kai, Lei JunQiang. Value of magnetic resonance morphological imaging in the diagnosis and differentiation of post-hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(12): 2587-2591. doi: 10.3969/j.issn.1001-5256.2018.12.016
    [13]Yang ErNa, Cao WuKui. Research advances in noninvasive diagnosis of hepatic fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2209-2213. doi: 10.3969/j.issn.1001-5256.2017.11.035
    [14]Du JingHua, Nan YueMin. Novel molecular diagnostic markers for liver fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 445-450. doi: 10.3969/j.issn.1001-5256.2017.03.009
    [15]Zhang Hui, Jia Lei, Lu: Dong, Xu YouQing. Value of serum cancer antigen12-5 level in diagnosis of peritoneal effusion in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(11): 2118-2120. doi: 10.3969/j.issn.1001-5256.2016.11.022
    [16]Deng Han, Qi XingShun, Zhu Qiang, Guo XiaoZhong. Alternative methods for diagnosis of esophageal varices in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1468-1473. doi: 10.3969/j.issn.1001-5256.2016.08.007
    [17]Zhao Wei. Clinical significance of plasma  and urine neutrophil gelatinase-associated lipocalin levels in diagnosis of acute kindney injury  in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(11): 1874-1877. doi: 10.3969/j.issn.1001-5256.2015.11.025
    [18]Wang Shuai, Hu DaRong. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites[J]. Journal of Clinical Hepatology, 2015, 31(7): 1018-1022. doi: 10.3969/j.issn.1001-5256.2015.07.005
    [19]Cai JunJun, Han Tao. Diagnosis and treatment of acute kidney injury in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1352-1356. doi: 10.3969/j.issn.1001-5256.2014.12.030
    [20]Jia KeDong, Shi ShuXian, Ruan YouBing. Detection of sialic acid in hepatitis involved liver cirrhosis and its significance for HCC diagnosis[J]. Journal of Clinical Hepatology, 2005, 21(2): 101-103.
  • Cited by

    Periodical cited type(6)

    1. 朱亭亭,陈逸云,谢帆慈,李正鑫. 无创评估肝纤维化逆转研究进展. 实用肝脏病杂志. 2025(02): 169-172 .
    2. 巴图德力根,韩志强,韩格根套丽,徐艳华,牧仁,安达. 德都红花-7味散及其主要成分对肝纤维化小鼠CCR1、DNMT1蛋白的作用研究. 中国临床药理学杂志. 2024(07): 1004-1008 .
    3. 张永,李艺,张欢. 复肝消积汤联合恩替卡韦治疗乙肝肝硬化代偿期的临床观察. 中国中西医结合消化杂志. 2023(02): 100-103+109 .
    4. 李定富,唐换灵,黄健,王秀琪. 血PⅢP、LN、HA水平与慢性肝炎程度、肝纤维化分期及炎症活动度分级的关系. 临床和实验医学杂志. 2022(10): 1119-1121 .
    5. 何杰,余松,董金玲,陈燕. 复元活血汤治疗肝硬化疗效观察及对肝脏纤维化的影响. 新中医. 2021(18): 29-32 .
    6. 刘沁雨,常越,张青,丁玉平,李海. 高尔基体蛋白73对抗病毒治疗慢性乙型肝炎患者代偿期肝硬化的诊断价值. 解放军医药杂志. 2020(03): 86-91 .

    Other cited types(6)

  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0405101520
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 8.5 %FULLTEXT: 8.5 %META: 86.3 %META: 86.3 %PDF: 5.2 %PDF: 5.2 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.0 %其他: 5.0 %China: 0.2 %China: 0.2 %India: 0.2 %India: 0.2 %United States: 0.7 %United States: 0.7 %[]: 0.9 %[]: 0.9 %上海: 2.6 %上海: 2.6 %东莞: 0.2 %东莞: 0.2 %北京: 6.4 %北京: 6.4 %南京: 0.2 %南京: 0.2 %南宁: 0.2 %南宁: 0.2 %台州: 0.5 %台州: 0.5 %合肥: 0.2 %合肥: 0.2 %吉林: 0.9 %吉林: 0.9 %哥伦布: 0.2 %哥伦布: 0.2 %墨尔本: 0.2 %墨尔本: 0.2 %太原: 0.9 %太原: 0.9 %常州: 0.2 %常州: 0.2 %广州: 0.9 %广州: 0.9 %张家口: 0.9 %张家口: 0.9 %成都: 1.7 %成都: 1.7 %昆明: 0.5 %昆明: 0.5 %杭州: 0.2 %杭州: 0.2 %森尼韦尔: 0.5 %森尼韦尔: 0.5 %温州: 0.2 %温州: 0.2 %湖州: 0.9 %湖州: 0.9 %漳州: 0.2 %漳州: 0.2 %芒廷维尤: 32.3 %芒廷维尤: 32.3 %芝加哥: 0.7 %芝加哥: 0.7 %苏州: 0.7 %苏州: 0.7 %莫斯科: 0.9 %莫斯科: 0.9 %衢州: 0.2 %衢州: 0.2 %西宁: 35.8 %西宁: 35.8 %赤峰: 0.2 %赤峰: 0.2 %运城: 0.2 %运城: 0.2 %重庆: 0.2 %重庆: 0.2 %长春: 0.9 %长春: 0.9 %长沙: 0.5 %长沙: 0.5 %长治: 0.7 %长治: 0.7 %齐齐哈尔: 0.2 %齐齐哈尔: 0.2 %其他ChinaIndiaUnited States[]上海东莞北京南京南宁台州合肥吉林哥伦布墨尔本太原常州广州张家口成都昆明杭州森尼韦尔温州湖州漳州芒廷维尤芝加哥苏州莫斯科衢州西宁赤峰运城重庆长春长沙长治齐齐哈尔

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2311) PDF downloads(381) Cited by(12)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return